Ognian Neytchev
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ognian Neytchev has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Paul G. Shiels
Glasgow Geroscience Group School of Molecular Biosciences MVLS University of Glasgow Glasgow UK
5 shared publications Anna Witasp
Department of Clinical Science Intervention and Technology Division of Renal Medicine Karolinska Institutet Stockholm Sweden
2 shared publicationsKarolina Kublickiene
Department of Clinical Science Intervention and Technology Division of Renal Medicine Karolinska Institutet Stockholm Sweden
2 shared publicationsPeter Stenvinkel
Department of Clinical Science Intervention and Technology Division of Renal Medicine Karolinska Institutet Huddinge Sweden
2 shared publications- Thomas Ebert
Universitätsklinikum Leipzig, Deutschland
2 shared publications - Abdul Rashid Qureshi
Renal Medicine, Department of Clinical Sciences, Intervention and Technology, Karolinska University Hospital Huddinge, Karolinska Institutet, 14186 Stockholm, Sweden
1 shared publication
Latest Publications
- Open Access
- 22 October 2025
- Published by Wiley in Journal of Internal Medicine
- Vol. 298 (6) , 578-590
Ignoring the planet: A critical blind spot for research on ageing
Although research on ageing has largely concentrated on understanding the fundamental biology of the ageing process and devising pharmaceutical interventions in order to slow it down, increasing evidence has underscored the crucial role of environmental inputs across the life course and across generations, in shaping both individual and intergenerational trajectories of age‐related health. These include nutrition, air pollution, social deprivation, lifestyle factors, climate change and exposure to environmental toxins, including microplastics and nanoplastics. The development of the concept of the exposome of ageing and the emergence of the new field of ‘exposomics’ have identified a blind spot, in particular, for geroscience. The impact of the exposome affecting human ‘healthspan’ (i.e., years lived in good health), extending across generations, is significant and yet under‐explored in research. As such, it is under‐appreciated that the declining health of the planet will have intergenerational ripple effects, epigenetically priming adverse health in future generations. We discuss the capacity to manipulate our exposome to mitigate against such effects, by addressing root causes, rather than symptoms, of both physiological and planetary dysregulation, dysfunction and decay. We propose a systems‐based framework that reconnects research on ageing with exposomics and planetary ecology, creating a new field of ‘ecological or exposome pharmacology’, harnessing the activity of Nrf2 as a senotherapeutic intervention to improve trans‐ and intergenerational physiology in the face of declining planetary health.
- 22 October 2025
- Published by Wiley in Journal of Internal Medicine
- Vol. 298 (6) , 578-590
Open AccessIgnoring the planet: A critical blind spot for research on ageing
Although research on ageing has largely concentrated on understanding the fundamental biology of the ageing process and devising pharmaceutical interventions in order to slow it down, increasing evidence has underscored the crucial role of environmental inputs across the life course and across generations, in shaping both individual and intergenerational trajectories of age‐related health. These include nutrition, air pollution, social deprivation, lifestyle factors, climate change and exposure to environmental toxins, including microplastics and nanoplastics. The development of the concept of the exposome of ageing and the emergence of the new field of ‘exposomics’ have identified a blind spot, in particular, for geroscience. The impact of the exposome affecting human ‘healthspan’ (i.e., years lived in good health), extending across generations, is significant and yet under‐explored in research. As such, it is under‐appreciated that the declining health of the planet will have intergenerational ripple effects, epigenetically priming adverse health in future generations. We discuss the capacity to manipulate our exposome to mitigate against such effects, by addressing root causes, rather than symptoms, of both physiological and planetary dysregulation, dysfunction and decay. We propose a systems‐based framework that reconnects research on ageing with exposomics and planetary ecology, creating a new field of ‘ecological or exposome pharmacology’, harnessing the activity of Nrf2 as a senotherapeutic intervention to improve trans‐ and intergenerational physiology in the face of declining planetary health.
- Open Access
- 21 December 2024
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 80 (5)
An Expert Consensus Statement on Biomarkers of Aging for Use in Intervention Studies
Biomarkers of aging serve as important outcome measures in longevity-promoting interventions. However, there is limited consensus on which specific biomarkers are most appropriate for human intervention studies. This work aimed to address this need by establishing an expert consensus on biomarkers of aging for use in intervention studies via the Delphi method. A 3-round Delphi study was conducted using an online platform. In Round 1, expert panel members provided suggestions for candidate biomarkers of aging. In Rounds 2 and 3, they voted on 500 initial statements (yes/no) relating to 20 biomarkers of aging. Panel members could abstain from voting on biomarkers outside their expertise. Consensus was reached when there was ≥70% agreement on a statement/biomarker. Of the 460 international panel members invited to participate, 116 completed Round 1, 87 completed Round 2, and 60 completed Round 3. Across the 3 rounds, 14 biomarkers met consensus that spanned physiological (eg, insulin-like growth factor 1, growth-differentiating factor-15), inflammatory (eg, high sensitivity C-reactive protein, interleukin-6), functional (eg, muscle mass, muscle strength, hand grip strength, Timed-Up-and-Go, gait speed, standing balance test, frailty index, cognitive health, blood pressure), and epigenetic (eg, DNA methylation/epigenetic clocks) domains. Expert consensus identified 14 potential biomarkers of aging which may be used as outcome measures in intervention studies. Future aging research should identify which combination of these biomarkers has the greatest utility.
- 21 December 2024
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 80 (5)
Open AccessAn Expert Consensus Statement on Biomarkers of Aging for Use in Intervention Studies
Biomarkers of aging serve as important outcome measures in longevity-promoting interventions. However, there is limited consensus on which specific biomarkers are most appropriate for human intervention studies. This work aimed to address this need by establishing an expert consensus on biomarkers of aging for use in intervention studies via the Delphi method. A 3-round Delphi study was conducted using an online platform. In Round 1, expert panel members provided suggestions for candidate biomarkers of aging. In Rounds 2 and 3, they voted on 500 initial statements (yes/no) relating to 20 biomarkers of aging. Panel members could abstain from voting on biomarkers outside their expertise. Consensus was reached when there was ≥70% agreement on a statement/biomarker. Of the 460 international panel members invited to participate, 116 completed Round 1, 87 completed Round 2, and 60 completed Round 3. Across the 3 rounds, 14 biomarkers met consensus that spanned physiological (eg, insulin-like growth factor 1, growth-differentiating factor-15), inflammatory (eg, high sensitivity C-reactive protein, interleukin-6), functional (eg, muscle mass, muscle strength, hand grip strength, Timed-Up-and-Go, gait speed, standing balance test, frailty index, cognitive health, blood pressure), and epigenetic (eg, DNA methylation/epigenetic clocks) domains. Expert consensus identified 14 potential biomarkers of aging which may be used as outcome measures in intervention studies. Future aging research should identify which combination of these biomarkers has the greatest utility.
- Open Access
- 12 October 2023
- Published by Wiley in Journal of Internal Medicine
- Vol. 295 (1) , 79-90
Epigenetic clocks indicate that kidney transplantation and not dialysis mitigate the effects of renal ageing
Background: Chronic kidney disease (CKD) is an age‐related disease that displays multiple features of accelerated ageing. It is currently unclear whether the two treatment options for end‐stage kidney disease (dialysis and kidney transplantation [KT]) ameliorate the accelerated uremic ageing process.Methods: Data on clinical variables and blood DNA methylation (DNAm) from CKD stage G3–G5 patients were used to estimate biological age based on blood biomarkers (phenotypic age [PA], n = 333), skin autofluorescence (SAF age, n = 199) and DNAm (Horvath, Hannum and PhenoAge clocks, n = 47). In the DNAm cohort, we also measured the change in biological age 1 year after the KT or initiation of dialysis. Healthy subjects recruited from the general population were included as controls.Results: All three DNAm clocks indicated an increased biological age in CKD G5. However, PA and SAF age tended to produce implausibly large estimates of biological age in CKD G5. By contrast, DNAm age was 4.9 years (p = 0.005) higher in the transplantation group and 5.9 years (p = 0.001) higher in the dialysis group compared to controls. This age acceleration was significantly reduced 1 year after KT, but not after 1 year of dialysis.Conclusions: Kidney failure patients displayed an increased biological age as estimated by DNAm clocks compared to population‐based controls. Our results suggest that KT, but not dialysis, partially reduces the age acceleration.
- 12 October 2023
- Published by Wiley in Journal of Internal Medicine
- Vol. 295 (1) , 79-90
Open AccessEpigenetic clocks indicate that kidney transplantation and not dialysis mitigate the effects of renal ageing
Background: Chronic kidney disease (CKD) is an age‐related disease that displays multiple features of accelerated ageing. It is currently unclear whether the two treatment options for end‐stage kidney disease (dialysis and kidney transplantation [KT]) ameliorate the accelerated uremic ageing process.Methods: Data on clinical variables and blood DNA methylation (DNAm) from CKD stage G3–G5 patients were used to estimate biological age based on blood biomarkers (phenotypic age [PA], n = 333), skin autofluorescence (SAF age, n = 199) and DNAm (Horvath, Hannum and PhenoAge clocks, n = 47). In the DNAm cohort, we also measured the change in biological age 1 year after the KT or initiation of dialysis. Healthy subjects recruited from the general population were included as controls.Results: All three DNAm clocks indicated an increased biological age in CKD G5. However, PA and SAF age tended to produce implausibly large estimates of biological age in CKD G5. By contrast, DNAm age was 4.9 years (p = 0.005) higher in the transplantation group and 5.9 years (p = 0.001) higher in the dialysis group compared to controls. This age acceleration was significantly reduced 1 year after KT, but not after 1 year of dialysis.Conclusions: Kidney failure patients displayed an increased biological age as estimated by DNAm clocks compared to population‐based controls. Our results suggest that KT, but not dialysis, partially reduces the age acceleration.
- 30 April 2023
- Published by Springer Nature
- Vol. 103, 79-94
Chronic Kidney Disease and the Exposome of Ageing
The gap between improvements in lifespan and age-related health is widening. Globally, the demographic of ageing is increasing and there has emerged a ‘diseasome of ageing’, typified by a range of non-communicable diseases which share a common underlying component of a dysregulated ageing process. Within this, chronic kidney disease is an emerging global epidemic. The extensive inter-individual variation displayed in how people age and how their diseasome manifests and progresses, has required a renewed focus on their life course exposures and the interplay between the environment and the (epi)genome. Termed the exposome, life course abiotic and biotic factors have a significant impact on renal health. We explore how the exposome of renal ageing can predispose and affect CKD progression. We discuss how the kidney can be used as a model to understand the impact of the exposome in health and chronic kidney disease and how this might be manipulated to improve health span. Notably, we discuss the manipulation of the foodome to mitigate acceleration of ageing processes by phosphate and to explore use of emerging senotherapies. A range of senotherapies, for removing senescent cells, diminishing inflammatory burden and either directly targeting Nrf2, or manipulating it indirectly via modification of the microbiome are discussed. Keywords Kidney Phosphate Ageing Exposome Senotherapy
- 30 April 2023
- Published by Springer Nature
- Vol. 103, 79-94
Chronic Kidney Disease and the Exposome of Ageing
The gap between improvements in lifespan and age-related health is widening. Globally, the demographic of ageing is increasing and there has emerged a ‘diseasome of ageing’, typified by a range of non-communicable diseases which share a common underlying component of a dysregulated ageing process. Within this, chronic kidney disease is an emerging global epidemic. The extensive inter-individual variation displayed in how people age and how their diseasome manifests and progresses, has required a renewed focus on their life course exposures and the interplay between the environment and the (epi)genome. Termed the exposome, life course abiotic and biotic factors have a significant impact on renal health. We explore how the exposome of renal ageing can predispose and affect CKD progression. We discuss how the kidney can be used as a model to understand the impact of the exposome in health and chronic kidney disease and how this might be manipulated to improve health span. Notably, we discuss the manipulation of the foodome to mitigate acceleration of ageing processes by phosphate and to explore use of emerging senotherapies. A range of senotherapies, for removing senescent cells, diminishing inflammatory burden and either directly targeting Nrf2, or manipulating it indirectly via modification of the microbiome are discussed. Keywords Kidney Phosphate Ageing Exposome Senotherapy
- Top Cited Papers
- 15 November 2021
- Published by SAGE Publications in Antioxidants & Redox Signaling
- Vol. 35 (17) , 1426-1448
Inflammation and Oxidative Stress in Chronic Kidney Disease and Dialysis Patients
Significance: Chronic kidney disease (CKD) can be regarded as a burden of lifestyle disease that shares common underpinning features and risk factors with the aging process; it is a complex constituted by several adverse components, including chronic inflammation, oxidative stress, early vascular aging, and cellular senescence. Recent Advances: A systemic approach to tackle CKD, based on mitigating the associated inflammatory, cell stress, and damage processes, has the potential to attenuate the effects of CKD, but it also preempts the development and progression of associated morbidities. In effect, this will enhance health span and compress the period of morbidity. Pharmacological, nutritional, and potentially lifestyle-based interventions are promising therapeutic avenues to achieve such a goal. Critical Issues: In the present review, currents concepts of inflammation and oxidative damage as key patho-mechanisms in CKD are addressed. In particular, potential beneficial but also adverse effects of different systemic interventions in patients with CKD are discussed. Future Directions: Senotherapeutics, the nuclear factor erythroid 2-related factor 2–kelch-like ECH-associated protein 1 (NRF2-KEAP1) signaling pathway, the endocrine klotho axis, inhibitors of the sodium–glucose cotransporter 2 (SGLT2), and live bio-therapeutics have the potential to reduce the burden of CKD and improve quality of life, as well as morbidity and mortality, in this fragile high-risk patient group. Antioxid. Redox Signal. 35, 1426–1448.
- 15 November 2021
- Published by SAGE Publications in Antioxidants & Redox Signaling
- Vol. 35 (17) , 1426-1448
Top Cited PapersInflammation and Oxidative Stress in Chronic Kidney Disease and Dialysis Patients
Significance: Chronic kidney disease (CKD) can be regarded as a burden of lifestyle disease that shares common underpinning features and risk factors with the aging process; it is a complex constituted by several adverse components, including chronic inflammation, oxidative stress, early vascular aging, and cellular senescence. Recent Advances: A systemic approach to tackle CKD, based on mitigating the associated inflammatory, cell stress, and damage processes, has the potential to attenuate the effects of CKD, but it also preempts the development and progression of associated morbidities. In effect, this will enhance health span and compress the period of morbidity. Pharmacological, nutritional, and potentially lifestyle-based interventions are promising therapeutic avenues to achieve such a goal. Critical Issues: In the present review, currents concepts of inflammation and oxidative damage as key patho-mechanisms in CKD are addressed. In particular, potential beneficial but also adverse effects of different systemic interventions in patients with CKD are discussed. Future Directions: Senotherapeutics, the nuclear factor erythroid 2-related factor 2–kelch-like ECH-associated protein 1 (NRF2-KEAP1) signaling pathway, the endocrine klotho axis, inhibitors of the sodium–glucose cotransporter 2 (SGLT2), and live bio-therapeutics have the potential to reduce the burden of CKD and improve quality of life, as well as morbidity and mortality, in this fragile high-risk patient group. Antioxid. Redox Signal. 35, 1426–1448.
- Open Access
Extracellular Vesicles, Ageing, and Therapeutic Interventions
A more comprehensive understanding of the human ageing process is required to help mitigate the increasing burden of age-related morbidities in a rapidly growing global demographic of elderly individuals. One exciting novel strategy that has emerged to intervene involves the use of extracellular vesicles to engender tissue regeneration. Specifically, this employs their molecular payloads to confer changes in the epigenetic landscape of ageing cells and ameliorate the loss of functional capacity. Understanding the biology of extracellular vesicles and the specific roles they play during normative ageing will allow for the development of novel cell-free therapeutic interventions. Hence, the purpose of this review is to summarise the current understanding of the mechanisms that drive ageing, critically explore how extracellular vesicles affect ageing processes and discuss their therapeutic potential to mitigate the effects of age-associated morbidities and improve the human health span.
Open AccessExtracellular Vesicles, Ageing, and Therapeutic Interventions
A more comprehensive understanding of the human ageing process is required to help mitigate the increasing burden of age-related morbidities in a rapidly growing global demographic of elderly individuals. One exciting novel strategy that has emerged to intervene involves the use of extracellular vesicles to engender tissue regeneration. Specifically, this employs their molecular payloads to confer changes in the epigenetic landscape of ageing cells and ameliorate the loss of functional capacity. Understanding the biology of extracellular vesicles and the specific roles they play during normative ageing will allow for the development of novel cell-free therapeutic interventions. Hence, the purpose of this review is to summarise the current understanding of the mechanisms that drive ageing, critically explore how extracellular vesicles affect ageing processes and discuss their therapeutic potential to mitigate the effects of age-associated morbidities and improve the human health span.
- Open Access
- 5 January 2018
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 19 (1) , 157
Telomere Homeostasis: Interplay with Magnesium
Telomere biology, a key component of the hallmarks of ageing, offers insight into dysregulation of normative ageing processes that accompany age-related diseases such as cancer. Telomere homeostasis is tightly linked to cellular metabolism, and in particular with mitochondrial physiology, which is also diminished during cellular senescence and normative physiological ageing. Inherent in the biochemistry of these processes is the role of magnesium, one of the main cellular ions and an essential cofactor in all reactions that use ATP. Magnesium plays an important role in many of the processes involved in regulating telomere structure, integrity and function. This review explores the mechanisms that maintain telomere structure and function, their influence on circadian rhythms and their impact on health and age-related disease. The pervasive role of magnesium in telomere homeostasis is also highlighted.
- 5 January 2018
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 19 (1) , 157
Open AccessTelomere Homeostasis: Interplay with Magnesium
Telomere biology, a key component of the hallmarks of ageing, offers insight into dysregulation of normative ageing processes that accompany age-related diseases such as cancer. Telomere homeostasis is tightly linked to cellular metabolism, and in particular with mitochondrial physiology, which is also diminished during cellular senescence and normative physiological ageing. Inherent in the biochemistry of these processes is the role of magnesium, one of the main cellular ions and an essential cofactor in all reactions that use ATP. Magnesium plays an important role in many of the processes involved in regulating telomere structure, integrity and function. This review explores the mechanisms that maintain telomere structure and function, their influence on circadian rhythms and their impact on health and age-related disease. The pervasive role of magnesium in telomere homeostasis is also highlighted.